Genetic therapy Market Size Grows to KRW 50 trillion in 2032
May 29, 2025
|
The U.S. market research firm Market & Market predicts that the global gene therapy market, which was about $7.2 billion (about KRW 10 trillion) in 2023, will grow at an annual average of 19.4% over the next nine years to form about $36.6 billion by 2032, according to a report by the Korea Bio Association.
By type, 'gene silence', a treatment that inhibits or blocks the expression of certain genes to prevent them from making proteins, is about $3.4 billion (about 4.7 trillion won) in 2023; 'gene enhancement', which is a method of adding normal genes to complement genes, is about $2.1 billion (about 2.9 trillion won), 'cell replacement', which replaces damaged cells with healthy cells, is about $1.5 billion (about 2 trillion won), and other treatments are worth $180 million (about 246.8 billion).
By treatment area, neurology accounted for 57.4% of the market with about $4.1 billion (about 5.6 trillion won) due to the increasing incidence of chronic diseases and increased demand for advanced treatments.
The size of the gene therapy market by region was the largest in North America with $3.56 billion (4.8836 trillion won), followed by Europe with $2.36 billion (3.2374 trillion won) and Asia Pacific with $920 million (1.2618 trillion won).
Meanwhile, domestic companies are also paying attention to the gene therapy market. Samsung Bioepis has identified gene therapy as one of the next-generation growth engines, and ABL Bio is also pushing to expand its scope to gene therapy. Algonomics signed a strategic licensing agreement with Eli Lilly this month to co-develop a precision RNA treatment for the treatment of hereditary hearing loss. The Ministry of Food and Drug Safety also pointed out strengthening the development of gene therapy as one of the characteristics of clinical trials conducted last year.
This article was translated by Naver AI translator.
